Ozempic & Zepbound Are Changing America in Ways Nobody Expected
On The Pen™ GLP-1 News
4,560 views
Zepbound isn’t just changing people’s weight. GLP-1 medications are beginning to change America itself.
Restaurants are rethinking what they serve. Grocery baskets are changing. Food companies are paying attention to protein and portion size. Employers and insurers are wrestling with the enormous cost of covering obesity treatment. And pharmaceutical companies are spending billions trying to build the drugs that come after Zepbound.
This week on On The Pen, The Weekly Dose, we’re connecting those dots.
We get into the next generation of obesity medicines, including retatrutide, eloralintide, amylin combinations and oral GLP-1s, plus the growing race to preserve muscle while producing even greater weight loss.
But there is another side to this story.
As the science gets better, access may actually be getting worse. Coverage restrictions are forcing patients off medications that work, employers are reconsidering GLP-1 benefits, and we’re approaching a strange moment where medicine may finally have extraordinarily effective treatments for obesity while millions of people still can’t afford them.
And then there’s McDonald’s.
When one of the largest restaurant companies in the world starts thinking differently about what consumers want in the GLP-1 era, this isn’t just a pharmaceutical story anymore.
It’s a cultural one.
🎙️ On The Pen, The Weekly Dose
Recorded from the Bask Health Studios
Https://www.bask.health
This Episode is Brought to you by:
Voafit and the MyLevel App
Https://www.Voafit.com/otp
Follow On The Pen and find everything I’m working on here:
linktr.ee/manonthemounjaro
In this episode: Retatrutide • Zepbound • Mounjaro • Ozempic • Wegovy • Eloralintide • Oral GLP-1s • Amylin • Muscle preservation • GLP-1 insurance coverage • The changing American food industry
This content is for informational purposes and is not medical advice.
20 Comments
Love listening to your podcast from across the pond in UK Dave ❤
Maybe it’s time for a class action lawsuit against all these health insurance companies.
Great podcast and explains why we must continue the fight for access for all!!
Ozempic & Zepbound Are Changing America in Ways Nobody Expected
On The Pen™ GLP-1 News
4,560 views
Zepbound isn’t just changing people’s weight. GLP-1 medications are beginning to change America itself.
Restaurants are rethinking what they serve. Grocery baskets are changing. Food companies are paying attention to protein and portion size. Employers and insurers are wrestling with the enormous cost of covering obesity treatment. And pharmaceutical companies are spending billions trying to build the drugs that come after Zepbound.
This week on On The Pen, The Weekly Dose, we’re connecting those dots.
We get into the next generation of obesity medicines, including retatrutide, eloralintide, amylin combinations and oral GLP-1s, plus the growing race to preserve muscle while producing even greater weight loss.
But there is another side to this story.
As the science gets better, access may actually be getting worse. Coverage restrictions are forcing patients off medications that work, employers are reconsidering GLP-1 benefits, and we’re approaching a strange moment where medicine may finally have extraordinarily effective treatments for obesity while millions of people still can’t afford them.
And then there’s McDonald’s.
When one of the largest restaurant companies in the world starts thinking differently about what consumers want in the GLP-1 era, this isn’t just a pharmaceutical story anymore.
It’s a cultural one.
🎙️ On The Pen, The Weekly Dose
Recorded from the Bask Health Studios
Https://www.bask.health
This Episode is Brought to you by:
Voafit and the MyLevel App
Https://www.Voafit.com/otp
Follow On The Pen and find everything I’m working on here:
linktr.ee/manonthemounjaro
In this episode: Retatrutide • Zepbound • Mounjaro • Ozempic • Wegovy • Eloralintide • Oral GLP-1s • Amylin • Muscle preservation • GLP-1 insurance coverage • The changing American food industry
This content is for informational purposes and is not medical advice.